Effect of Thyroid Disorders in Liver Diseases

Assiut University

Status: Not yet enrolling

Conditions: Fatty Liver Disease

Treatments: Device: Fibroscan

Study type: Observational

Funder types: Other

Identifiers

NCT06071923

04-2023-200396

Details and patient eligibility

About

Aims of the Research

1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD).
2. To detect hepatic risk in subclinical and clinical hypothyroidism .
3. To detect early liver disorders in thyroid disorders using fibroscan .

Full description

Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time.

considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future..

Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis.

In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism.

The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH.

In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction.

Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Enrollment: 140 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The study will include thyroid patients over one year duration ( age above 18 years old

Exclusion criteria

1. History of liver failure or patient known to have congenital liver disease.
2. Medications associated with weight gain .
3. Patients who have diabetes mellitus.
4. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis.
5. Patients on antistatin.